SCHEMBL322142

SCHEMBL322142

Oc1cc(Cl)c(-c2cccc(C(F)(F)F)c2)cc1I

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RORB Q92753 4/20 0.49
RORC P51449 3/20 0.49
MAPT P10636 2/20 0.47
THRA P10827 1/20 0.43
THRB P10828 1/20 0.43
ALOX15 P16050 1/20 0.41
ALOX12 P18054 1/20 0.41
SLC2A1 P11166 1/20 0.41
P2RX1 P51575 1/20 0.41
P2RX4 Q99571 1/20 0.41
P2RX7 Q99572 1/20 0.41
TMPRSS4 Q9NRS4 1/20 0.41
CNR2 P34972 1/20 0.41
PTPN5 P54829 1/20 0.40
DPP4 P27487 1/20 0.40
CNR1 P21554 1/20 0.39
MEN1 O00255 1/20 0.39
GAA P10253 1/20 0.39
HPGD P15428 1/20 0.39
KMT2A Q03164 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL322242 0.80 ESR2 (0.43) MAPTTHRBALOX15ALOX12DPP4
SCHEMBL322331 0.77 RORB (0.52) RORBRORCMAPTTHRATHRB
SCHEMBL323025 0.77 RORB (0.44) RORBRORCMAPTTHRATHRB
SCHEMBL323510 0.76 KIF11 (0.48) MAPTALOX15ALOX12CNR2
SCHEMBL322244 0.74 ESR2 (0.43) MAPTALOX15ALOX12MEN1HPGD
SCHEMBL28146422 0.74 AKR1C3 (0.43) RORBRORCMAPTALOX15ALOX12
SCHEMBL13549883 0.73 ESR2 (0.59) RORBRORCMAPTTHRATHRB
SCHEMBL2048141 0.73 PTPN5 (0.69) RORBRORCMAPTALOX15ALOX12
SCHEMBL30689246 0.73 PTPN5 (0.69) RORBRORCMAPTALOX15ALOX12
SCHEMBL21620303 0.73 MAOB (0.50) RORBRORCMAPTPTPN5HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2590951-B1 BENZENESULFONAMIDES USEFUL AS SODIUM CHANNEL INHIBITORS PFIZER LTD (GB) 2015-01-07 EP disclosed
EP-2590951-B1 BENZENESULFONAMIDES USEFUL AS SODIUM CHANNEL INHIBITORS PFIZER LTD (GB) 2015-01-07 EP disclosed
US-8772293-B2 Chemical compounds PFIZER LIMITED (GB) 2014-07-08 US disclosed
US-8772293-B2 Chemical compounds PFIZER LIMITED (GB) 2014-07-08 US disclosed
US-8772293-B2 Chemical compounds PFIZER LIMITED (GB) 2014-07-08 US disclosed
EP-2590951-A1 BENZENESULFONAMIDES USEFUL AS SODIUM CHANNEL INHIBITORS Pfizer Limited (GB) 2013-05-15 EP disclosed
WO-2012004743-A1 BENZENESULFONAMIDES USEFUL AS SODIUM CHANNEL INHIBITORS PFIZER LIMITED (GB) 2012-01-12 WO disclosed
WO-2012004743-A1 BENZENESULFONAMIDES USEFUL AS SODIUM CHANNEL INHIBITORS PFIZER LIMITED (GB) 2012-01-12 WO disclosed
US-20120010182-A1 Chemical Compounds ICAGEN INC. (US) 2012-01-12 US disclosed
US-20120010182-A1 Chemical Compounds ICAGEN INC. (US) 2012-01-12 US disclosed
US-20120010182-A1 Chemical Compounds ICAGEN INC. (US) 2012-01-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120010182-A1 Chemical Compounds SCN1A, SCN1B, CACNA1E RORB 1724/4885RORC 1898/4885MAPT 3814/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.